Search
GR270773
go.drugbank.com/drugs/DB06427Investigationalinfusion between healthy adults and those with damaged livers) and NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a
Tyloxapol
go.drugbank.com/drugs/DB06439ApprovedInvestigationalTyloxapol is a non-ionic detergent often used as a surfactant.
Categories: Compounds used in a research, industrial, or household settingDexanabinol
go.drugbank.com/drugs/DB06444InvestigationalCategories: Compounds used in a research, industrial, or household settingALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.
PW2101
go.drugbank.com/drugs/DB06483ExperimentalPW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.
Mirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI.
Velafermin
go.drugbank.com/drugs/DB06493InvestigationalVelafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated
S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
MLN2704
go.drugbank.com/drugs/DB06513InvestigationalA Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.
Astaxanthin
go.drugbank.com/drugs/DB06543InvestigationalAstaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. … It may be found in fish feed or some animal food as a color additive.
Mixtures: VitaHealth L-Glutathione Plus